IPSS-M在慢性粒单核细胞白血病中的评估
本研究为多中心回顾性研究,纳入511例CMML患者,评估分子国际预后评分系统(IPSS-M)的预后价值。IPSS-M可有效分层患者的总生存(OS)和AML进展累积发生率,合并重叠中危组后得到4层模型,OS的C-index为0.678,AML进展为0.628。该模型在MD-CMML和MP-CMML亚组中均保持预后性能,且与iCPSS预后性能相当,优于CPSS-Mol。
要点
- IPSS-M可对CMML患者进行有效的OS和AML进展风险分层。
- 合并重叠中危组后4层模型OS的C-index为0.678,AML进展为0.628。
- adapted IPSS-M预后性能与iCPSS相当,优于CPSS-Mol。
核心结论
- adapted IPSS-M适用于CMML,可扩展至骨髓增生异常综合征之外的疾病。
- 本研究为iCPSS在独立且遗传学特征明确的CMML队列中提供了外部验证。
研究设计与样本
- 多中心回顾性研究,纳入511例诊断为CMML的患者。
- 收集诊断时临床、细胞遗传学和分子数据,包括靶向二代测序。
- 使用IPSS-M、CPSS-Mol和iCPSS对患者进行分层。
主要发现
- IPSS-M有效分层患者,风险组间总生存(OS)和急性髓系白血病(AML)进展累积发生率显著不同。
- 合并重叠中危组后得到4层模型,OS的C-index为0.678,AML进展为0.628。
- 该模型在MD-CMML和MP-CMML亚组中均保持预后性能,MD-CMML组OS区分度更高。
- adapted IPSS-M预后性能与iCPSS相当,优于CPSS-Mol。
关键数值与推荐
- 4层模型OS的C-index为0.678,AML进展的C-index为0.628。
临床怎么用
- adapted IPSS-M可用于CMML患者的预后分层,指导临床决策和治疗策略。
- iCPSS在独立CMML队列中得到外部验证,支持其临床实用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prognostication in chronic myelomonocytic leukemia (CMML) remains a challenge because of the biological complexity and variable clinical course of the disease. This study aimed to evaluate the prognostic utility of the Molecular International Prognostic Scoring System (IPSS-M) in CMML and its applicability across the myelodysplastic (MD) and myeloproliferative (MP) subsets of the disease. We conducted a multicenter, retrospective study including 511 patients diagnosed with CMML. Clinical, cytogenetic, and molecular data were collected at diagnosis, including targeted next-generation sequencing. Patients were stratified using IPSS-M, the molecular CMML-specific prognostic scoring system (CPSS-Mol), and the recently developed international CPSS (iCPSS). IPSS-M effectively stratified patients into risk groups with significantly different overall survival (OS) and cumulative incidence of acute myeloid leukemia (AML) progression. Discrimination was maintained after merging overlapping intermediate-risk categories, yielding a 4-tier model with a C-index of 0.678 for OS and 0.628 for AML progression, respectively. This model retained its prognostic performance in both MD-CMML and MP-CMML subsets, with a higher discrimination for OS in the MD-CMML group. When compared with CPSS-Mol and iCPSS, adapted IPSS-M showed comparable prognostic performance to iCPSS and improved discrimination compared with CPSS-Mol. These findings support the applicability of an adapted IPSS-M to CMML, extending its use beyond myelodysplastic syndromes and highlighting its potential utility in guiding clinical decision-making and therapeutic strategies. Moreover, this study provides an external validation of the iCPSS in an independent and genetically well-characterized CMML cohort, reinforcing its clinical utility.
引用
- Palomo L, Morgades M, Meggendorfer M, et al. Assessment of the IPSS-M in chronic myelomonocytic leukemia. Blood Adv. 2026. PMID: 42532514. doi:10.1182/bloodadvances.2026019760
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。